Straits Times Index
3,337.55 +7.54 (+0.23%) Nikkei
38,703.51 +213.34 (+0.55%) Hang Seng
18,461.53 +36.57 (+0.20%) FTSE 100
8,256.64 +9.69 (+0.12%) Bitcoin USD
70,949.79 -193.60 (-0.27%) CMC Crypto 200
1,518.71 -6.09 (-0.40%)
Mind Medicine Inc (MMQ.SG)
| Previous close | 6.74 |
| Open | 6.68 |
| Bid | 6.68 x N/A |
| Ask | 6.82 x N/A |
| Day's range | 6.68 - 6.68 |
| 52-week range | 2.23 - 12.16 |
| Volume | |
| Avg. volume | 2,699 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
MindMed to Participate in June Conferences
NEW YORK, May 28, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following conferences:
- Business Wire
MindMed to Present at Upcoming May Medical Conferences
NEW YORK, April 25, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:
- Business Wire
MindMed to Present at Upcoming April Medical Conferences
NEW YORK, April 02, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:
